María Eva Mingot‐Castellano
A5036366385- Platelet Disorders and Treatments
- Hemophilia Treatment and Research
- Blood groups and transfusion
- Complement system in diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Lymphocytic Leukemia Research
- Autoimmune Bullous Skin Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Hemostasis and retained surgical items
- Immunodeficiency and Autoimmune Disorders
- Blood disorders and treatments
- Iron Metabolism and Disorders
- Chronic Myeloid Leukemia Treatments
- Blood properties and coagulation
- CAR-T cell therapy research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Renal Transplantation Outcomes and Treatments
- Venous Thromboembolism Diagnosis and Management
- Erythropoietin and Anemia Treatment
- Multiple Myeloma Research and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Cell Adhesion Molecules Research
- Lymphoma Diagnosis and Treatment
Instituto de Biomedicina de Sevilla
2022-2025
Hospital Universitario Virgen del Rocío
2005-2025
Universidad de Sevilla
2024-2025
Hospital Regional Universitario de Málaga
2014-2024
Catholic University of Ávila
2023
Hospital Universitario de Burgos
2023
Hospital Universitario Río Hortega
2023
Spanish Society of Hematology and Hemotherapy
2023
Hospital Doctor José Molina Orosa
2012-2019
GTx (United States)
2015-2018
Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of present spontaneous and an isolated prolonged aPTT. AHA may, however, without any symptoms, therefore aPTT should always be investigated further irrespective the clinical findings. Control acute first priority, we recommend first-line therapy bypassing agents such as recombinant activated FVII or...
Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation factor (F) VIII. It characterized soft tissue in patients without personal or family history of bleeding. Bleeding variable, ranging from acute, life-threatening hemorrhage, with 9-22% mortality, mild that requires no treatment. AHA usually presents clinicians prior experience the disease, therefore diagnosis frequently delayed and bleeds under treated.Structured literature searches were used...
Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when treatment withdrawn but the frequency of this phenomenon unknown. We retrospectively evaluated 260 adult primary ITP (165 women 95 men; median age, 62 years) treated with eltrombopag after a time from diagnosis 24 months. Among 201 who achieved complete remission (platelet count >100 × 10(9) /l), was discontinued 80 patients. Reasons for discontinuation were: persistent...
Abstract Immune thrombotic thrombocytopenic purpura (iTTP) is a microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab approved for adults with an acute episode of iTTP in conjunction plasma exchange (PEX) and immunosuppression. The objective this study was to analyze compare the safety efficacy caplacizumab vs standard care assess effect concomitant use rituximab. A retrospective from Spanish TTP Registry patients treated those who did not receive it conducted. total 155 (77...
Introduction There has been increasing recognition in recent years that female carriers of haemophilia manifest abnormal bleeding; however, data on the use bleeding assessment tools this population are lacking. Aim Our objective was to validate ISTH ‐ BAT describe symptoms and allow for comparisons with factor levels other patient groups. Methods This a prospective, observational, cross‐sectional study performed by members Global Emerging HE mostasis Panel ( GEHEP ). Unselected consecutive...
Summary The thrombopoietin receptor agonists ( THPO ‐ RA s), romiplostim and eltrombopag, are effective safe in immune thrombocytopenia ITP ). However, the value of their sequential use when no response is achieved or adverse events occur with one has not been clearly established. Here we retrospectively evaluated 51 primary adult patients treated followed by eltrombopag. median age our cohort was 49 (range, 18–83) years. There were 32 women 19 men. duration before switching to eltrombopag...
Evans syndrome (ES) is a rare condition, defined as the presence of 2 autoimmune cytopenias, most frequently hemolytic anemia and immune thrombocytopenia (ITP) rarely neutropenia. ES can be classified primary or secondary to various conditions, including lymphoproliferative disorders, other systemic diseases, immunodeficiencies, particularly in children. In adult ES, little known about clinical features, disease associations, outcomes. this retrospective international study, we analyzed 116...
Summary Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as second‐line treatment for ITP. Real‐world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed 6.8%; persistent 13.6%; chronic 79.5%;...
Abstract Objectives The main objective was to analyse the Zarit scale's (ZS) ability identify signs of caregiver collapse amongst people looking after patients suffering from dementia. We also evaluated dimensions most affected by ZS and risk factors associated with burden collapse. Methods administered semi‐structured interviews 66 patient: age, sex, type dementia, place residence, length illness, behavioural disorders, incontinence, Barthel index (IB), Global Deterioration Scale (GDS),...
Summary Treatment adherence in adolescents with chronic diseases is around 50%, and failure more common preventive therapy. In haemophilia, contradictory results are reported by the published studies. The objective of this study was to evaluate factor VIII (FVIII) prophylaxis Spanish patients severe haemophilia A between age 6 20 years. Data were collected retrosp‐ectively previous 2 primary endpoint absolute index (AAI), endpoints related clinical status, age, regimen, responsibility for...
Patients with multirefractory immune thrombocytopenia (ITP) have limited treatment options. Recent data suggest that specific anti-platelet antibodies may cause destruction of platelets by favoring platelet loss sialic acid. In this multicenter study 35 patients ITP, including 16 disease, were analyzed for antiplatelet-antibodies, thrombopoietin (TPO) levels, and desialylation. selected cases, responses to a novel strategy using oseltamivir tested.We found against GPIbα overrepresented in...
Molecular diagnosis of patients with von Willebrand disease is pending in most populations due to the complexity and high cost conventional molecular analyses. The need for clinical characterization Spain prompted creation a multicenter project (PCM-EVW-ES) that resulted largest prospective cohort study all types disease. analysis relevant regions VWF, including intronic promoter regions, was achieved 556 individuals recruited via development simple, innovative, relatively low-cost protocol...
The diagnosis of von Willebrand disease (VWD) remains difficult in a significant proportion patients. A Spanish multicentre study investigated cohort 556 patients from 330 families who were analysed centrally. VWD was confirmed 480. Next generation sequencing (NGS) the whole coding VWF carried out all recruited patients, compared with phenotype, and final established. total 238 different mutations found, 154 not included Leiden Open Variation Database (LOVD). Of 463 found to have mutation/s....
Summary Sparse data are available on presentation and management of acute coronary syndromes ( ACS ), including unstable angina non‐ ST ‐ ‐elevation myocardial infarction, among persons with haemophilia PWH ). The aim this study was to determine demographics, bleeding disorder characteristics, cardiovascular risk factors CRF s), interventions, haemostatic protocol, revascularization outcomes complications . Members an international consortium comprising >2000 adult retrospectively...
The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included retrospectively followed for a median 12 months. Patients predominantly male (56.3%), with age at diagnosis 74 years. was more frequently idiopathic (44.1%) autoimmune disorder-associated (31.7%). Thirty-four percent on antithrombotic therapy diagnosis. Hemostatic treatment used 70% patients. Recombinant activated factor VII infused (60.3% vs...
Objectives Patients with severe haemophilia A ( HA ) receive factor VIII FVIII replacement therapy as prophylaxis. my PKF iT ® is an online medical application that allows authorized users to simulate dosing regimens patient pharmacokinetic PK profiles based on only 2 blood samples. Our aim was assess the impact of using this device in routine practice terms consumption and clinical outcomes. Methods Thirty‐six patients prophylaxis Advate were recruited 3 centres Spain. Annual bleeding rate...